Danaher Corp
Close on Nov 2, 2026Market cap $160.26BP/E 40.5Yield –
Danaher Life Sciences — Core Sales Growth by Quarter
Life Sciences — Core Sales Growth (%) (%)
Danaher Life Sciences — Core Sales Growth: 4.5% in Q3 2026, up 5.5 pts from a year earlier.
Where the Q3 2026 figure comes from
Source: Danaher IR — nongaap_2026Q3 ↗
Includes SCIEX, Beckman Coulter Life Sciences, Leica Microsystems, Molecular Devices, Phenomenex, IDT, Aldevron, and Abcam.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Life Sciences — Core Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 4.5% | +5.5 pts | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2026 | Jun 30, 2026 | 5.5% | +8.0 pts | Danaher IR — nongaap_2026Q2 ↗ |
| Q1 2026 | Mar 31, 2026 | 0.5% | +4.5 pts | Danaher IR — nongaap_2026Q1 ↗ |
| Q4 2025 | Dec 31, 2025 | 0.5% | -0.5 pts | Danaher IR — nongaap_2025Q4 ↗ |
| Q3 2025 | Sep 30, 2025 | -1.0% | +1.0 pts | Danaher IR — nongaap_2025Q3 ↗ |
| Q2 2025 | Jun 30, 2025 | -2.5% | +3.0 pts | Danaher IR — nongaap_2025Q2 ↗ |
| Q1 2025 | Mar 31, 2025 | -4.0% | -1.0 pts | Danaher IR — nongaap_2025Q1 ↗ |
| Q4 2024 | Dec 31, 2024 | 1.0% | +5.0 pts | Danaher IR — nongaap_2024Q4 ↗ |
| Q3 2024 | Sep 30, 2024 | -2.0% | +0.5 pts | Danaher IR — nongaap_2024Q3 ↗ |
| Q2 2024 | Jun 30, 2024 | -5.5% | -11.0 pts | Danaher IR — nongaap_2024Q2 ↗ |
| Q1 2024 | Mar 31, 2024 | -3.0% | -8.0 pts | Danaher IR — nongaap_2024Q1 ↗ |
| Q4 2023 | Dec 31, 2023 | -4.0% | -17.0 pts | Danaher IR — nongaap_2023Q4 ↗ |
| Q3 2023 | Sep 30, 2023 | -2.5% | -13.0 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2023 | Jun 30, 2023 | 5.5% | +0.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2023 | Mar 31, 2023 | 5.0% | -4.0 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2022 | Dec 31, 2022 | 13.0% | -4.0 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q3 2022 | Sep 30, 2022 | 10.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2022 | Jun 30, 2022 | 5.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2022 | Mar 31, 2022 | 9.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2021 | Dec 31, 2021 | 17.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
Breakdown
What makes up life Sciences — Core Sales Growth
Cite this data
StockData. (2026). Danaher Life Sciences — Core Sales Growth (%), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/core-sales-growth-lifesci
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.